Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00137293 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating GAP-486 in Heart Rhythm
A Phase 2 study, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- Terminated
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT00137293 is a Phase 2 study that was terminated before completion, run by Wyeth is now a wholly owned subsidiary of Pfizer. The registered enrollment target is 30 participants.
The verdict
NCT00137293, a Phase 2 study, was terminated before completion, sponsored by Wyeth is now a wholly owned subsidiary of Pfizer.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.
Interventions
- DRUG GAP-486 (ZP-123)
- DRUG 0.9% Sodium Chloride, USP
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2005-11 |
| Est. Completion | 2006-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00137293
The ClinicalTrials.gov registry entry for NCT00137293 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which GAP-486 (ZP-123) is the first listed.
NCT00137293 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00137293 about?
NCT00137293 is a clinical study titled "Study Evaluating GAP-486 in Heart Rhythm". The purpose of this study is to learn the effects of a test drug on heart rhythm, and to provide additional data to see if the test drug is well tolerated and safe.
What is the current status of trial NCT00137293?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2005-11. Estimated completion is 2006-10.
What interventions are being tested in trial NCT00137293?
The interventions under investigation include: GAP-486 (ZP-123) (DRUG), 0.9% Sodium Chloride, USP (DRUG).
Who is sponsoring clinical trial NCT00137293?
This trial is sponsored by Wyeth is now a wholly owned subsidiary of Pfizer, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.